Discovery Engine News Today

NEW HAVEN, Conn., June 03, 2024 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will...

Tuskegee University has become the latest partner of the Center for Research on Programmable Plant Systems (CROPPS), a Science and Technology Center funded by the U.S. National Science Foundation aimed at developing tools to communicate with plants and the associated organisms that make up their microbiomes.

NEW HAVEN, Conn., May 02, 2024 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will...

Do you scroll through Pinterest looking for cute pet accessories? The world of pet accessories on Pinterest appears to have an irresistible charm, ranging from stylish bandanas to eccentric toys. What is the main motivation behind the obsession of people with pet accessories?In this article, we will go over why pet accessories are so popular […]

The dynamic world of Pinterest allows you to combine sound and image to create an unforgettable experience that your fans will never forget. How indie rock bands captivate their audience not just through music but also with captivating visuals? Can the visual charm of indie rock bands on Pinterest truly enhance their presence and fan […]

Have you ever wondered why Pinterest has such a magical touch, not just on your creative impulses, but also in the plethora of other apps around you? It’s more than just a visual paradise of pins and boards; it has a profound impact on the engagement levels of various apps Here are some interesting facts […]

Invaio Sciences has acquired Peptyde Bio to bring an established platform and IP portfolio enabling Invaio to speed up the design and discovery of peptides

-- Arvinas has an average buy rating and a price target range of $20 to $110, according to analysts polled by Capital IQ. Price: 30.39, Change: +7.22, Percent Change: +31.14 ...

NEW HAVEN, Conn., Nov. 27, 2023 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered...

NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced